Journal
THROMBOSIS RESEARCH
Volume 218, Issue -, Pages 8-16Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.thromres.2022.08.003
Keywords
Splanchnic vein; Thrombosis; Myeloproliferative; Polycythemia vera; Essential thrombocythemia; Myelofibrosis
Categories
Funding
- American Cancer Society [129819-IRG-16-189-58-IRG-114]
- American Heart Association Career Development Award [OT2 HL15275801]
Ask authors/readers for more resources
This review summarizes the epidemiology, pathogenic features, and clinical management of myeloproliferative neoplasm (MPN) with splanchnic vein thrombosis (SVT), highlighting the central role of endothelial cells in this condition.
Splanchnic vein thrombosis (SVT) in the setting of myeloproliferative neoplasm (MPN) is a unique clinical entity that requires close interdisciplinary coordination for proper diagnosis and management. The pathobiology of MPN-SVT is not fully understood, but recent developments have revealed the central role of endothelial cells. In this multidisciplinary review, we summarize the epidemiology of MPN-SVT and then critically evaluate the pathogenic features of this complication, with a focus on endothelial cell biology. We then discuss diagnostic considerations, including imaging modalities and MPN-specific investigations. Finally, we critically review the evidence supporting clinical management of MPN-SVT, including anticoagulation, interventional radiology procedures, MPN-related therapies, and liver transplantation. We conclude that further studies are needed to improve our understanding of MPN-SVT and the outcomes of patients with this debilitating complication.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available